Abstract: This review explores the role of DAPT in stem cell biology, specifically focusing on its application in direct cardiac reprogramming. While the acronym DAPT is widely recognized in cardiovascular medicine as Dual Antiplatelet Therapy, in the context of regenerative medicine, DAPT refers to a specific synthetic small molecule: (S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl) acetamido) propanamido)-2-phenylacetate. As a potent Notch signaling pathway inhibitor, DAPT enhances the transdifferentiation of cardiac fibroblasts into induced cardiomyocytes (iCMs) by preventing the suppression of the crucial cardiogenic transcription factor Mef2c. This review synthesizes current knowledge on DAPT's pharmacological activity, molecular mechanism, and future perspectives in optimizing cell culture conditions for myocardial regeneration.
1. Introduction
Ischemic heart diseases and heart failure are leading causes of mortality, primarily because terminally differentiated cardiomyocytes lack the potential for self-renewal [1]. Following a myocardial infarction, necrotic cardiomyocytes are replaced by proliferating fibroblasts, leading to the formation of fibrotic scar tissue that severely impairs cardiac systolic function [1]. To address this, regenerative medicine has explored pathways such as differentiating induced pluripotent stem cells (iPSCs) into cardiomyocytes or employing "direct cardiac reprogramming" to convert resident cardiac fibroblasts directly into induced cardiomyocytes (iCMs) in situ [1].
In the broader medical literature, the term "DAPT" frequently appears in cardiovascular research as an acronym for Dual Antiplatelet Therapy, a standard pharmacological strategy used to prevent thrombosis following percutaneous coronary intervention or stent implantation [2][3][4]. However, in the specific context of stem cell biology and direct cardiac reprogramming, DAPT refers to a targeted synthetic compound used to enhance the efficiency of cell fate conversion [1]. This review focuses exclusively on the chemical compound DAPT and its role in advancing cardiac regenerative therapies.
2. Pharmacological Activity
The primary pharmacological activity of the compound DAPT in stem cell biology is the enhancement of direct cardiac reprogramming [1]. The baseline reprogramming of fibroblasts into iCMs—typically driven by the introduction of cardiogenic transcription factors such as Gata4, Mef2c, and Tbx5 (GMT)—often suffers from low induction efficiency [1]. The addition of DAPT to the reprogramming protocol significantly improves this efficiency, facilitating a more robust conversion of fibroblasts into functional, mature cardiomyocytes [1].
3. Molecular Mechanism of Action
DAPT functions as a specific inhibitor of the Notch signaling pathway [1]. During the direct reprogramming of fibroblasts into cardiomyocytes, the transcription factor Mef2c plays a master regulatory role in activating cardiogenic gene expression [1]. However, Notch signaling actively suppresses Mef2c transcription, acting as a molecular barrier to cell fate conversion [1]. By inhibiting the Notch signaling pathway, DAPT relieves this suppression, thereby increasing Mef2c transcriptional activity and synergistically promoting the genome-wide activation of cardiogenic stage-specific enhancers [1].
4. Structure-Activity Relationship (SAR)
The chemical identity of DAPT is defined as (S)-tert-butyl 2-((S)-2-(2-(3,5-difluorophenyl) acetamido) propanamido)-2-phenylacetate [1]. While the provided literature explicitly identifies this complex structure and its targeted action against the Notch signaling pathway, detailed structure-activity relationship (SAR) studies modifying its functional groups (such as the difluorophenyl or tert-butyl moieties) are not elaborated upon in the current text [1]. Its current structural conformation is highly optimized for Notch inhibition in the context of in vitro cell culture applications to enhance reprogramming [1].
5. Current Limitations
While DAPT successfully enhances reprogramming, the broader application of this technology faces several limitations. First, human fibroblasts are inherently more resistant to reprogramming than mouse fibroblasts, requiring additional factors (such as Mesp1 and Myocd) and exhibiting slower progression [1]. Second, age and inflammation act as significant barriers; older fibroblasts upregulate the COX-2/PGE2/EP4/IL-1β inflammatory pathway, which actively suppresses cardiomyocyte induction [1]. Finally, translating these chemically enhanced reprogramming protocols to in vivo clinical applications requires safe gene delivery methods, as traditional retroviral vectors pose risks of genomic integration and host cell damage [1].
6. Future Perspectives
The future of DAPT in stem cell biology lies in its integration into highly optimized, defined culture conditions. Research has shown that combining Notch inhibitors like DAPT with other signaling modulators—such as TGF-β and Wnt inhibitors, or growth factors like FGF-2, FGF-10, and VEGF—can exponentially increase the yield of beating iCMs [1]. Furthermore, combining these optimized chemical cocktails with non-integrating delivery systems, such as Sendai virus vectors, holds promise for safe in vivo cardiac regeneration [1]. Ultimately, refining the use of compounds like DAPT could pave the way for personalized regenerative therapies and novel drug screening platforms for various heart diseases [1].
